Comparing Organon & Co. (OGN) & Its Rivals

Organon & Co. (NYSE:OGN) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Organon & Co. to related businesses based on the strength of its dividends, risk, valuation, analyst recommendations, earnings, profitability and institutional ownership.

Profitability

This table compares Organon & Co. and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.49%	82.06%	6.03%
Organon & Co. Competitors	-2,372.59%	-220.82%	-15.99%

Institutional and Insider Ownership

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 1.6% of Organon & Co. shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Organon & Co. has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, Organon & Co.’s peers have a beta of -4.05, suggesting that their average share price is 505% less volatile than the S&P 500.

Dividends

Organon & Co. pays an annual dividend of $0.08 per share and has a dividend yield of 0.6%. Organon & Co. pays out 10.5% of its earnings in the form of a dividend. As a group, “Pharmaceuticals” companies pay a dividend yield of 3.3% and pay out 48.0% of their earnings in the form of a dividend.

Earnings & Valuation

This table compares Organon & Co. and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Organon & Co.	$6.22 billion	$187.00 million	18.20
Organon & Co. Competitors	$3.54 billion	$3.17 billion	554.50

Organon & Co. has higher revenue, but lower earnings than its peers. Organon & Co. is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current recommendations for Organon & Co. and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2	5	0	0	1.71
Organon & Co. Competitors	7792	13886	25777	1037	2.41

Organon & Co. presently has a consensus price target of $11.40, suggesting a potential downside of 17.60%. As a group, “Pharmaceuticals” companies have a potential upside of 25.67%. Given Organon & Co.’s peers stronger consensus rating and higher possible upside, analysts plainly believe Organon & Co. has less favorable growth aspects than its peers.

Summary

Organon & Co. peers beat Organon & Co. on 8 of the 15 factors compared.

About Organon & Co.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.